Rapamycin preserves renal function compared with cyclosporine A after ischemia/reperfusion injury - 26/08/11
Abstract |
Objectives |
To determine the effect of cyclosporine and rapamycin administration on renal function after ischemia/reperfusion injury (I/R). Cyclosporine A has known nephrotoxic effects. Thus, cyclosporine therapy subsequent to I/R injury may further exacerbate graft dysfunction. Rapamycin is a newer agent that suppresses the immune system by a different mechanism.
Methods |
Male Wistar rats (250 g) were anesthetized, and the suprarenal aorta was clamped for 40 minutes. The right kidney was removed. After recovery, the rats were divided into four groups: group 1, controls, no ischemia and no treatment (n = 10); group 2, ischemia with no treatment (n = 8); group 3, ischemia plus rapamycin (0.17 mg/kg/day gavage, n = 8); and group 4, ischemia plus cyclosporine A (30 mg/kg/day intraperitoneally, n = 9). The glomerular filtration rate was measured 5 to 7 days after I/R injury using urinary iohexol clearance. Data are expressed as the mean ± SEM, and intergroup comparisons were made using one-way analysis of variance.
Results |
The mean GFR value for the controls (no ischemia, no treatment) was 1.23 ± 0.08 mL/min; for group 2 (ischemia, no treatment), it was 1.05 ± 0.10 mL/min; for group 3 (ischemia plus rapamycin) 1.06 ± 0.14 mL/min; and for group 4 (ischemia plus cyclosporine A) 0.44 ± 0.06 mL/min (P <0.05 versus the other three groups). The mean arterial pressure was significantly lower in the ischemic rats treated with cyclosporine A (P <0.05 versus the other three groups).
Conclusions |
After I/R injury, rapamycin may preserve renal function compared with cyclosporine treatment, because it does not have a direct vasoconstrictor effect on the renal microcirculation.
Le texte complet de cet article est disponible en PDF.Plan
This study was supported by the Donald Seldin, M.D. Young Investigator Grant of the National Kidney Foundation. |
Vol 62 - N° 4
P. 750-754 - octobre 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?